LMO2 is a specific marker of T-lymphoblastic leukemia/lymphoma

Dragan Jevremovic, Anja Roden, Rhett P. Ketterling, Paul J. Kurtin, Ellen McPhail

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Objectives: The diagnosis of T-lymphoblastic leukemia/lymphoma (T-ALL) involving the thymus can be difficult to establish since neoplastic T lymphoblasts show significant phenotypic overlap with both normal thymocytes and thymocytes from epithelial thymic neoplasms (thymomas). LIMDomain Only 2 (LMO2) gene translocations have been implicated in the pathogenesis of a small subset of T-ALLs, and LMO2 protein has recently been reported to be expressed in a large proportion of T-ALLs. Methods: In this study, we tested specificity of LMO2 for distinction between neoplastic and nonneoplastic T-precursor cells in thymus and bone marrow. Results: Our findings show that LMO2 is expressed in neoplastic lymphoblasts of T-ALL and is absent in thymocytes of normal thymuses or thymomas. Conclusions: LMO2 is therefore a useful marker for immunophenotypic assessment of thymic neoplasms.

Original languageEnglish (US)
Pages (from-to)180-190
Number of pages11
JournalAmerican Journal of Clinical Pathology
Volume145
Issue number2
DOIs
StatePublished - Feb 1 2016

    Fingerprint

Keywords

  • Immunohistochemistry
  • LMO2
  • T-ALL

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this